Aktienanalyse zu Cardiff Oncology Inc (CRDF)CRDFCardiff Oncology Inc

Cardiff Oncology, Inc. is a clinical-stage biotechnology company advancing cancer treatments focused on Polo-like Kinase 1 (PLK1) inhibition, a validated oncology target with practice-changing potential. The Company's lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor being evaluated in a Phase II trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML). The Company's clinical development programs incorporate tumor genomics and biomarker assays to refine patient selection and assessment of patient response to treatment. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Currently, Cardiff Oncology Inc (CRDF) is not a strong buy due to its low current price of $0.8443 and a 52-week change of -61.97%. The RSI is at 33.314, indicating it is nearing oversold territory, which could suggest a potential for recovery. However, the company has reported significant net losses, with a net income of -9.24 million in Q2 2026, and a forward P/E ratio of 0, which raises concerns about profitability. The main risk is the ongoing legal dispute affecting its lead drug candidate, which could impact future revenue and stock performance.